Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Jersey's wellbeing score is below UK and France - 2NASA's Voyager 1 set to achieve historic distance from Earth
- 3Rebecca Gayheart on her 'very complicated' relationship with Eric Dane: 'I am always going to want the best for him'
- 4Barry Manilow reveals lung cancer diagnosis and plans to undergo surgery: 'It's pure luck' it was 'found so early'
- 5A throat bone settles it - Nanotyrannus was not a juvenile T. rex
- Instructions to Choose the Best Web based Advertising Degree Program for Your Objectives
- Portugal among EU countries with the most people working close to 50 hours a week
- Barn Stored Lotus Esprit Turbo Seen After 30 Years
- Vote In favor of Your Favored Web-based Visual depiction Administration
- Nurturing Hacks: Shrewdness from Experienced Mothers and Fathers
- Most loved Occasion Dish: What Makes Your Merry Table?
- Bismuth’s haredi draft bill won’t change enlistment, IDI expert tells 'Post'
- EU-funded BioSupPack project turns brewery waste into bioplastics
- I visited every country by 25. Antarctica showed me how much I still hadn't seen.
